M A Posternak1, I Miller. 1. Department of Psychiatry and Human Behavior, Brown University School of Medicine, Rhode Island Hospital, 235 Plain St., Suite 501, Providence, RI 02905, USA. mposternak@lifespan.org
Abstract
INTRODUCTION: While the short-term response rates to antidepressant medication and placebo are well established, very little is known about the short-term course of untreated depression. Knowledge of the course of untreated depression can serve as a benchmark for assessing the true benefits of active treatment. METHOD: A meta-analysis was performed analyzing the outcomes of all psychotherapy studies that randomized adult outpatients with major depressive disorder to a wait-list control group. RESULTS: Nineteen studies involving 221 subjects were reviewed. The mean decrease in Hamilton Rating Scale for Depression scores over 2-20 weeks was 11.9%, while the mean decrease in Beck Depression Inventory scores was 15.7%. Using a subsample of studies that reported individual outcomes, we estimated that 15 of 76 subjects (19.7%) improved to a degree comparable to what would be considered a positive response in antidepressant trials. CONCLUSIONS: In the short-term, depressive symptomatology can be expected to decrease by about 10-15% on average without treatment. As many as 20% of subjects who participate in a short-term antidepressant trial may experience a spontaneous remission.
INTRODUCTION: While the short-term response rates to antidepressant medication and placebo are well established, very little is known about the short-term course of untreated depression. Knowledge of the course of untreated depression can serve as a benchmark for assessing the true benefits of active treatment. METHOD: A meta-analysis was performed analyzing the outcomes of all psychotherapy studies that randomized adult outpatients with major depressive disorder to a wait-list control group. RESULTS: Nineteen studies involving 221 subjects were reviewed. The mean decrease in Hamilton Rating Scale for Depression scores over 2-20 weeks was 11.9%, while the mean decrease in Beck Depression Inventory scores was 15.7%. Using a subsample of studies that reported individual outcomes, we estimated that 15 of 76 subjects (19.7%) improved to a degree comparable to what would be considered a positive response in antidepressant trials. CONCLUSIONS: In the short-term, depressive symptomatology can be expected to decrease by about 10-15% on average without treatment. As many as 20% of subjects who participate in a short-term antidepressant trial may experience a spontaneous remission.
Authors: T Munder; C Flückiger; F Leichsenring; A A Abbass; M J Hilsenroth; P Luyten; S Rabung; C Steinert; B E Wampold Journal: Epidemiol Psychiatr Sci Date: 2018-07-30 Impact factor: 6.892
Authors: Matthew S Milak; John Keilp; Ramin V Parsey; Maria A Oquendo; Kevin M Malone; J John Mann Journal: J Affect Disord Date: 2010-04-09 Impact factor: 4.839
Authors: Willemijn Hoek; Monika Marko; Joshua Fogel; Josien Schuurmans; Tracy Gladstone; Nathan Bradford; Rocco Domanico; Blake Fagan; Carl Bell; Mark A Reinecke; Benjamin W Van Voorhees Journal: Transl Res Date: 2011-08-19 Impact factor: 7.012
Authors: Bret R Rutherford; Shoko Mori; Joel R Sneed; Monique A Pimontel; Steven P Roose Journal: J Psychiatr Res Date: 2012-03-10 Impact factor: 4.791